These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 25809274)
1. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Kim EJ; Semrad TJ; Bold RJ Expert Opin Investig Drugs; 2015 Jun; 24(6):781-94. PubMed ID: 25809274 [TBL] [Abstract][Full Text] [Related]
2. Drug development and clinical trial design in pancreatico-biliary malignancies. Harrington J; Carter L; Basu B; Cook N Curr Probl Cancer; 2018; 42(1):73-94. PubMed ID: 29402439 [TBL] [Abstract][Full Text] [Related]
3. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. Rahib L; Fleshman JM; Matrisian LM; Berlin JD JAMA Oncol; 2016 Sep; 2(9):1209-16. PubMed ID: 27270617 [TBL] [Abstract][Full Text] [Related]
6. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Kaur J; Singh P; Enzler T; Sahai V Expert Opin Emerg Drugs; 2021 Jun; 26(2):103-129. PubMed ID: 33734833 [No Abstract] [Full Text] [Related]
7. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Mosquera C; Maglic D; Zervos EE Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577 [TBL] [Abstract][Full Text] [Related]
8. Novel agents in the treatment of pancreatic adenocarcinoma. Dimou A; Syrigos KN; Saif MW JOP; 2013 Mar; 14(2):138-40. PubMed ID: 23474556 [TBL] [Abstract][Full Text] [Related]
9. Emerging drugs in the treatment of pancreatic cancer. Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902 [TBL] [Abstract][Full Text] [Related]
10. Cetuximab: still an option in the treatment of pancreatic cancer? Faloppi L; Andrikou K; Cascinu S Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505 [TBL] [Abstract][Full Text] [Related]
11. Emerging antibodies for the treatment of pancreatic cancer. Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833 [TBL] [Abstract][Full Text] [Related]
12. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Douglas JE; Liu S; Ma J; Wolff RA; Pant S; Maitra A; Tamm EP; Bhosale P; Katz MHG; Varadhachary GR; Koay EJ BMC Cancer; 2022 Jan; 22(1):14. PubMed ID: 34980020 [TBL] [Abstract][Full Text] [Related]
13. Second line treatment options for pancreatic cancer. Passero FC; Saif MW Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270 [TBL] [Abstract][Full Text] [Related]
14. Emerging drugs in the treatment of advanced gastric cancer. Tetzlaff ED; Cen P; Ajani JA Expert Opin Emerg Drugs; 2008 Mar; 13(1):135-44. PubMed ID: 18321153 [TBL] [Abstract][Full Text] [Related]
15. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma. Amoroso L; Haupt R; Garaventa A; Ponzoni M Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153 [TBL] [Abstract][Full Text] [Related]
16. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394 [TBL] [Abstract][Full Text] [Related]
17. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008. Saif MW JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919 [TBL] [Abstract][Full Text] [Related]
18. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF Eur J Pharm Sci; 2018 Mar; 115():296-303. PubMed ID: 29366960 [TBL] [Abstract][Full Text] [Related]
19. [Possibilities of palliation in pancreatic cancer]. Di Costanzo F; Sdrobolini A; Gasperoni S Tumori; 1999; 85(1 Suppl 1):S47-53. PubMed ID: 10235081 [TBL] [Abstract][Full Text] [Related]
20. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Matera R; Saif MW Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]